US-based Constellation Pharmaceuticals has appointed Emma Reeve as its chief financial officer to bolster the biopharma’s finance efforts.
Following over two decades’ worth of experience across pharmaceutical, medical device and biopharma companies, Reeve’s most recent role saw her serve as interim chief financial officer and corporate controller of Parexel International, where she was responsible for financial reporting, accounting, investor relations and financial planning.
She has also held senior finance roles at Novartis, Merck and Bristol-Myers Squibb.
Additionally, Brad Prosek (pictured left) joins Constellation Pharmaceuticals as senior vice president, corporate development, from All Terrain bioPartners, where he advised and supported a set of life sciences clients on transaction, corporate and commercial strategy and execution.
Prior to that he spent ten years at Cubist Pharmaceuticals, Biogen and Covance.
Jigar Raythatha, president and chief executive officer, Constellation Pharmaceuticals, said: “Emma and Brad each bring highly relevant experiences to Constellation, including capital market expertise, business development, and the commercialisation of novel therapies.
“This past summer we re-organised our R&D leadership and recruiting Emma and Brad provides pivotal business leadership as we chart our path forward.”